Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Dublin 2
Tel: 353-1-669-8559 or 800-462-3636
Fax: 800-329-3636
Website: http://www.endo.com/
305 articles about Endo International plc
-
Endo Begins Shipment of Generic Kuvan® Tablets and Powder for Oral Solution (sapropterin dihydrochloride)
10/1/2020
Endo International plc (NASDAQ: ENDP) today announced that its subsidiary, Par Pharmaceutical, Inc. (Par), has begun shipping sapropterin dihydrochloride tablets, 100 mg, and powder for oral solution, 100 mg and 500 mg, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application
-
Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
9/25/2020
Endo International plc announced that its subsidiary, Par Sterile Products, LLC has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax' COVID-19 vaccine candidate.
-
Endo International’s subsidiary, Par Sterile Products, LLC, has agreed to provide fill-finish manufacturing services to Novavax for commercial distribution of the vaccine company’s nanoparticle COVID-19 vaccine candidate.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
-
Endo to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)
9/24/2020
Endo International plc announced that it will present data relevant to the use of Qwo™ for the treatment of moderate to severe cellulite in the buttocks of adult women during Vegas Cosmetic Surgery & Aesthetic Dermatology.
-
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
-
Endo to Participate at Citi 15th Annual BioPharma Virtual Conference
9/8/2020
Endo International plc (NASDAQ: ENDP) announced today that it will participate in the Citi 15th Annual BioPharma Virtual Conference being held September 8-10, 2020.
-
Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer
8/21/2020
Endo International plc (the "Company") (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the "Offer") by its wholly owned subsidiary Endo Finance LLC ("Endo Finance") for any and all of its outstanding 5.75% Senior Notes due 2022 (the "Notes"), which expired at 5:00 p.m.,
-
Endo International plc Commences Tender Offer For Any And All Of Its Outstanding 5.75% Senior Notes Due 2022
8/17/2020
Endo International plc announced that Endo Finance LLC, a wholly-owned subsidiary of the Company, has commenced a cash tender offer for any and all of its outstanding 5.75% Senior Notes due 2022, on the terms and subject to the conditions set forth in the Offer to Purchase, dated as of the date hereof and the related Notice of Guaranteed Delivery attached to the Offer to Purchase.
-
Endo Announces Second Quarter 2020 Earnings Call Time Change
7/30/2020
Endo International plc (NASDAQ: ENDP) today announced that it has changed the time of its previously announced conference call in an attempt to reduce conflicts with other earnings calls.
-
Endo Appoints M. Christine Smith, Ph.D. to Board of Directors
7/29/2020
Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Christie Smith, Ph.D. to serve as a non-executive director, effective July 29, 2020
-
U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite
7/6/2020
Endo International plc (NASDAQ: ENDP) today announced that it received U.S. Food and Drug Administration (FDA) approval of Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.
-
Endo to Announce Second-Quarter 2020 Financial Results
6/16/2020
Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2020 financial results on August 6, 2020 and members of its senior management team will host a conference call and webcast at 7:30am ET before the U.S. financial markets open.
-
Endo International plc Announces Final Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
6/15/2020
More Than 97% Of Notes Sought Were Tendered And Accepted Thereby Extending More Than $2.7 Billion Of Endo International plc's Near-Term Debt Maturities
-
Endo International plc Announces Early Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
5/29/2020
Endo International plc (the "Company") (NASDAQ: ENDP) announced today the early tender results of the previously announced Exchange Offers and Consent Solicitations (each as defined below) by wholly owned subsidiaries Pa
-
Endo International plc Announces Proposed Exchange Offers And Consent Solicitations
5/14/2020
Endo International plc (the "Company") (NASDAQ:ENDP) announced today that its wholly owned subsidiaries, Par Pharmaceutical, Inc., a New York corporation ("PPI"), Endo Designated Activity Company, a designated activity company incorporated under the laws of Ireland ("Endo DAC"), Endo Finance LLC, a Delaware limited liability company ("End
-
Endo Reports First-Quarter 2020 Financial Results and Provides Update Relating to COVID-19 Pandemic
5/7/2020
Endo International plc reported financial results for the first quarter ended March 31, 2020 and provided an update relating to the impact of the COVID-19 pandemic.
-
Endo to Announce First Quarter 2020 Financial Results
4/16/2020
Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2020 financial results on May 7, 2020 and members of its senior management team will host a conference call and webcast at 8:00am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./ Canada (866) 497-0462, International (67
-
Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results
2/26/2020
Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth quarter and full year ended December 31, 2019.
-
Endo Names Blaise Coleman President and Chief Executive Officer
2/19/2020
Endo International plc announced that Blaise Coleman, who has served as the Company's Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020.